arrow
P

Pardeep S. Jhund

university of glasgow
H指数:95
被引数:4.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Heart failure with mid-range or preserved ejection fraction: temporal trends in an individual patient data meta-analysis of trials

射血分数中期或保留的心力衰竭:试验个体患者数据Meta分析中的时间趋势

2026-09-260
PRE
Diagnostic imaging modalities in Dyspnoea and suspected acute heart failure: a systematic review with Meta-analysis

呼吸困难及疑似急性心力衰竭的影像学诊断方法:一项系统评价与Meta分析

2026-09-210
OAAI
Personalized evaluation of NT-proBNP and clinical characteristics in suspected heart failure: the PRECISE-HF study

疑似心力衰竭患者中NT-proBNP和临床特征的个性化评估:PRECISE-HF研究

2026-08-280
OAAI
Finerenone benefits in patients with cardio-kidney-metabolic syndrome with or without history of cancer: the FINE-HEART pooled analysis

在有无癌症病史的心肾代谢综合征患者中非奈利酮的获益:FINE-HEART合并分析

2026-08-180
OAAI
Finerenone and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction

非奈利酮对射血分数轻度降低或保留的心力衰竭患者中表观治疗抵抗性高血压的影响

2026-08-170
OAAI
Comparative Prognosis of Chagas and Other Cardiomyopathies

Chagas与其他心肌病的比较预后

JACC
IF0
2026-03-160
PRE
Finerenone, polypharmacy, and clinical outcomes in heart failure: pre-specified analysis from the FINEARTS-HF trial

非奈利酮、多药治疗和心力衰竭患者的临床结局:FINEARTS-HF试验的预先指定分析

2026-01-010
OA
Finerenone-Related Risk of Hypotension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Finerenone相关的低血压风险:在轻度降低或保留射血分数的心力衰竭中

2025-12-090
OAAI
Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure

Finerenone及根据基线肾功能的心力衰竭患者心血管结局

2025-12-050
PRE
Timing of Cardiovascular and Kidney Benefits with Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes

Finerenone在心力衰竭和伴有2型糖尿病的慢性肾脏病中心血管和肾脏获益的时间点

JACC
IF0
2025-11-180
OAAI
Finerenone in patients with severe heart failure: The FINEARTS-HF trial

Finerenone 在严重心力衰竭患者中的应用:FINEARTS-HF 试验

2025-11-040
OAAI